Patterns of Triptans Use: A Study Based on the Records of a Community Pharmaceutical Department

Pavone, Eleonora; Banfi, Roberto; Vaiani, Monica; Panconesi, Alessandro

doi:10.1111/j.1468-2982.2007.01401.x

Cited by 35 publications

(44 citation statements)

References 17 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that the percentage of patients not persistent past their index triptan was nearly 54%; as compared to the 39% single-time use of triptans among those not on prophylactics found within a similar US-based population in the Etemad et al study (17). Our triptan persistency results are closer to the singletime triptan utilization results in ex-US populations, which range from 42% to 56% (11)(12)(13)15), and also do not differentiate between those on concomitant prophylactic therapies. Furthermore, patients in this study population are representative of US-based triptan users and migraineurs in general with respect to gender, age and comorbid disorders.…”

Section: Discussionsupporting

confidence: 72%

Triptan persistency among newly initiated users in a pharmacy claims database

Katić

Rajagopalan²,

et al. 2010

Cephalalgia

View full text Add to dashboard Cite

Migraine patients were more likely to discontinue their triptan after their index prescription than at any other time in their prescription refill history. The majority of patients did not persistently refill triptans, but filled prescriptions for non-specific migraine therapies such as opioids and non-steroidal anti-inflammatory drugs. Reasons for triptan discontinuation warrant further investigation.

show abstract

Section: Discussionsupporting

confidence: 72%

Triptan persistency among newly initiated users in a pharmacy claims database

Katić

Rajagopalan²,

et al. 2010

Cephalalgia

View full text Add to dashboard Cite

show abstract

“…Other studies describing the percentage of triptan users, in periods when more triptans are available, are reported in Table 4 [5, 6, 8–15]. The prevalence of triptan users in a year period was 0.55–1.4%.…”

Section: Literature Reviewmentioning

confidence: 99%

“…Utilization patterns of specific anti-migraine drugs in community patients and the experiences of patients with these drugs in real life setting have been studied less extensively. Recently we have performed a study evaluating triptans utilization in a health authority in Tuscany covering about 225,000 residents [4, 5]. We have extended this study to establish the patterns of use of triptans in a large sample of Italian population [6] and review other studies on this topic.…”

Section: Introductionmentioning

confidence: 99%

Triptans in the Italian population: a drug utilization study and a literature review

Panconesi¹,

Pavone²,

Vacca³

et al. 2008

J Headache Pain

View full text Add to dashboard Cite

Previous studies performed in selected populations show a poor utilization of triptans for migraine. The objectives of our study were to establish patterns of triptans utilization in a large sample, covering 1/10 of Italian population (5.57 millions), and to perform a review of published studies on this topic. We investigated drug prescription database collected during 2006 from 33 health authorities distributed in 8 different regions. About 0.6% of the subjects received at least one prescription of triptans in 1 year: 77.7% were females and 22.3% males. Age distribution shows that 9.5% of patients were aged above 65, and received prescriptions for 8.2% of packages. The review of the literature suggests that these percentages of utilization are common to several countries, and shows that occasional triptan users who received only one prescription in 1 year are a large percentage (40–60%); moreover, a minor population of triptan users utilize a large amount of total triptans. Finally triptans are frequently prescribed in people aged above 65 years, a population in which triptans are contraindicated or not recommended. Our study and the analyzed ones indicate suboptimal treatment of migraine patients with triptans and also an incorrect use in some patients (triptan abusers, elderly).

show abstract

“…In this controlled trial early administration of the triptan produced significantly greater symptomatic relief compared with treatment given when the pain had become more severe 16 . Thus, there appears to be a certain lack of association between current best-evidence relating to the diagnosis and management of migraine, and what occurs in the 'real world' 17 .…”

Section: Introductionmentioning

confidence: 98%